Answers are grounded in this paper and cite their sources.
Background Suicidal thoughts and behaviors (STBs) are heterogeneous in their causes and course, yet most interventions rely on nomothetic, one-size-fits-all models. Dialectical behavior therapy (DBT) is an evidence-based treatment for STBs, but its standard year-long format is resource-intensive and difficult to access. Ecological momentary assessment (EMA) combined with idiographic (person-specific) statistical modeling offers a way to identify which emotion regulation processes are driving an individual’s risk, and in turn to select the DBT skills most relevant for that person. Objective This protocol describes the refinement (aim 1) and preliminary evaluation (aim 2) of PRECISE (Personalized Clinical Intervention for Suicidal Events), an 8-week, EMA-informed, idiographically tailored adjunctive treatment for adults with active suicidal ideation. Methods In aim 1, an existing PRECISE treatment manual and clinician dashboard will be iteratively refined with a mentorship and advisory panel and tested for feasibility and acceptability in a small, randomized pilot study (n=10; n=5 per arm), comparing high- and low-intensity personalization schedules. In aim 2, 60 adults with active suicidal ideation will be randomized to a high-intensity (weekly idiographic model updates across all 8 EMA-monitored weeks) or low-intensity (single idiographic model generated after an initial 2-week EMA burst) version of PRECISE. Both arms will receive coach-delivered DBT skills selected according to each participant’s idiographic model, which will be generated using the group iterative multiple model estimation (GIMME) algorithm. Primary outcomes include usability, retention, EMA adherence, acceptability, and fidelity; secondary and exploratory analyses will examine trajectories of suicidal ideation and a within-person mediation model linking emotion regulation to STBs. Results The trial registration record (ClinicalTrials.gov) was first posted on February 5, 2025, and enrollment began on November 14, 2025. The study is currently recruiting. Estimated total enrollment across aim 1 and aim 2 is 70 participants. Primary and final data collection are anticipated to be complete by March 2030. The study was funded in May 2025, and data collection began in November 2025. As of November 9, 2026, 7 participants had been enrolled. Results are expected to be published in approximately the beginning of 2030. Conclusions PRECISE is, to our knowledge, the first idiographically personalized, EMA-informed adjunctive treatment developed specifically for STBs. This trial will provide feasibility, acceptability, and preliminary efficacy data to inform a subsequent fully powered efficacy trial. Trial Registration ClinicalTrials.gov NCT06809348; https://clinicaltrials.gov/study/NCT06809348 International Registered Report Identifier (IRRID) DERR1-10.2196/109277
No takes yet. Share an insight, caveat, or question.
Kuehn et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: